Skip to content
DE

Pramlintide: an add-on to insulin therapy and its risks

Clinical review pending

How pramlintide, an amylin analog, affects blood sugar after meals and why severe low blood sugar is a major risk.

What is pramlintide?

Pramlintide is a synthetic analog of amylin 1, a hormone the pancreas releases together with insulin after meals. It is not a GLP-1 drug, which sets it apart from many other injectable peptide medicines for diabetes.

Natural human amylin tends to clump together, which makes it hard to formulate as a medicine. In pramlintide, three amino acids were swapped out to improve solubility and stability while keeping its activity. AstraZeneca markets it as Symlin or SymlinPen, and it is injected under the skin before meals.

How does pramlintide work?

Pramlintide lowers blood sugar after meals by standing in for amylin. Normally this hormone works alongside insulin to regulate how quickly glucose enters the blood. Pramlintide acts in three ways: Source

  • It slows stomach emptying 1, so glucose is absorbed more gradually.

  • It suppresses the release of glucagon after meals, which insulin alone does not fully control. Source

  • Acting through the brain, it strengthens the feeling of fullness and reduces food intake.

Insulin helps glucose move into cells, while amylin helps set the timing of its entry into the blood. That is why pramlintide adds to mealtime insulin rather than replacing it. Typically it produces a small drop in HbA1c and moderate weight loss. Source

Is pramlintide FDA-approved?

Yes. Pramlintide was approved in 2005 and is sold under the name Symlin. The approval covers use as an add-on to mealtime insulin in adults with type 1 or type 2 diabetes who already use insulin but are not reaching their blood sugar targets. Source

What is pramlintide prescribed for?

Pramlintide is used as an add-on to mealtime insulin in adults with type 1 or type 2 diabetes whose blood sugar stays too high after meals despite insulin therapy. It is not used on its own. It is contraindicated in people with impaired awareness of low blood sugar and in people with gastroparesis, a marked slowing of stomach emptying.

What side effects have been reported?

According to the prescribing information, the most common side effects include:

  • Nausea.

  • Vomiting.

  • Reduced appetite.

  • Headache.

  • Low blood sugar.

The most serious risk is severe low blood sugar. Pramlintide carries a prominent warning known as a Boxed Warning 1: taken together with insulin, it can trigger severe insulin-induced hypoglycemia, usually within three hours of the injection. For this reason, doctors reduce the insulin dose when treatment begins. Particular caution is needed in people at high risk of low blood sugar.

Sources cited in the original article

Sources: FDA prescribing information for Symlin (pramlintide acetate).

Origin and editorial review status

Adapted for Nutrient Desk from the original article. The statements and source attributions of the original still require clinical review. This draft has not been cleared for indexing.